MedTrace Logo

Evaluation of the Predictive and Prognostic Value of Germ-line Polymorphisms in Patients With Metastatic Breast Cancer

NCT01460186 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2019-01-15

No results posted yet for this study

Summary

This is a multicenter, non-randomized, prospective cohort study. The purpose of the study is to identify germ line genetic factors that influence the risk of metastatic breast cancer.

1500 patients will be enrolled in this study. Blood samples will be collected after informed consent and inclusion in the study.

Patients will be treated and followed according to the standards of their treating center.

They will be followed during at least 5 years every 6 months for 3 years then every year.

Conditions

Interventions

OTHER

Blood sample for genetic analysis (Identification of germ line genetic factors that influence the risk of metastatic breast cancer)

Blood samples will be collected in one 6 ml EDTA and one 6 ml ACD tube after informed consent and inclusion in the study.

Sponsors & Collaborators

  • Centre de Recherche en Cancérologie de Lyon

    collaborator UNKNOWN

  • Centre Leon Berard

    lead OTHER

Principal Investigators

  • Thomas BACHELOT, MD · Centre Leon Berard

Study Design

Purpose
OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2017-09-01
Completion
2017-09-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01460186 on ClinicalTrials.gov